The role will include: developing the strategic thinking for critical pre-R2D work for rare disease including natural history and biomarker studies, planning the Phase I and/or Phase II studies and the overall Clinical Development Plans, building the portfolio in the emerging disease areas and partnering with Business Development and Research. A fully trained neurologist or experience in rare disease space would be suitable. The Senior Medical Director in Ophthalmology, Pain, New Indications will provide strategic leadership for several aspects of our emerging disease portfolio including neurological diseases spanning retinal and neurodevelopmental disorders. This person will also be responsible to determine whether other molecules in the Biogen portfolio or any Business Development emerging compounds are a good fit for the Company for additional indications.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior
Education Level
Ph.D. or professional degree
Number of Employees
1,001-5,000 employees